Optimizing Biotherapeutic Protein Expression With Novel GS® CHO Vector Technology

The biopharmaceutical industry needs to produce increasingly complex therapeutic proteins, from simple single-chain proteins to multi-chain bispecifics, with higher efficiency. CHO-based expression platforms are the go-to for this, but the big question is: how can we make them even better to keep up with demand?

While we've made great strides in process optimization to boost manufacturing yields, the key to continued progress lies in refining core components. DNA expression vectors are crucial to protein production, so their design significantly impacts overall yield.

Lonza has been tackling this challenge by improving its GS® expression vector technology. In this webinar, we share our latest breakthrough: a high-strength synthetic gene promoter. This innovation boosts protein titers while maintaining exceptional product quality and stable expression, ultimately leading to more efficient biomanufacturing for a wide array of molecules.